GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. 2017

Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota.

Maturation of human natural killer (NK) cells as defined by accumulation of cell-surface expression of CD57 is associated with increased cytotoxic character and TNF and IFNγ production upon target-cell recognition. Notably, multiple studies point to a unique role for CD57+ NK cells in cancer immunosurveillance, yet there is scant information about how they mature. In this study, we show that pharmacologic inhibition of GSK3 kinase in peripheral blood NK cells expanded ex vivo with IL15 greatly enhances CD57 upregulation and late-stage maturation. GSK3 inhibition elevated the expression of several transcription factors associated with late-stage NK-cell maturation including T-BET, ZEB2, and BLIMP-1 without affecting viability or proliferation. When exposed to human cancer cells, NK cell expanded ex vivo in the presence of a GSK3 inhibitor exhibited significantly higher production of TNF and IFNγ, elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity. In an established mouse xenograft model of ovarian cancer, adoptive transfer of NK cells conditioned in the same way also displayed more robust and durable tumor control. Our findings show how GSK3 kinase inhibition can greatly enhance the mature character of NK cells most desired for effective cancer immunotherapy. Cancer Res; 77(20); 5664-75. ©2017 AACR.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072283 A549 Cells An immortalized cell line derived from human ADENOCARCINOMA, ALVEOLAR basal epithelial cells isolated from the lungs of a male patient in 1972. The cell line is positive for KERATIN, can synthesize LECITHIN, and contains high levels of POLYUNSATURATED FATTY ACIDS in its PLASMA MEMBRANE. It is used as a model for PULMONARY ALVEOLI function and virus infections, as a TRANSFECTION host, and for PRECLINICAL DRUG EVALUATION. A549 Cell Line,A549 Cell,A549 Cell Lines,Cell Line, A549,Cell Lines, A549,Cell, A549,Cells, A549
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell

Related Publications

Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
January 2006, Immunologic research,
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
August 2022, Cancer research communications,
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
September 2021, The Journal of experimental medicine,
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
January 1984, Eksperimentalna meditsina i morfologiia,
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
September 2010, Endocrinology,
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
August 2004, Science (New York, N.Y.),
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
May 2021, Cellular & molecular immunology,
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
April 2023, International journal of cancer,
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
October 2022, Cancers,
Frank Cichocki, and Bahram Valamehr, and Ryan Bjordahl, and Bin Zhang, and Betsy Rezner, and Paul Rogers, and Svetlana Gaidarova, and Stacey Moreno, and Katie Tuininga, and Phillip Dougherty, and Valarie McCullar, and Peter Howard, and Dhifaf Sarhan, and Emily Taras, and Heinrich Schlums, and Stewart Abbot, and Daniel Shoemaker, and Yenan T Bryceson, and Bruce R Blazar, and Scott Wolchko, and Sarah Cooley, and Jeffrey S Miller
June 2024, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!